SYSTEM AND METHOD FOR IMPROVING BIOMARKER ASSAY
The present disclosure pertains to detection of biomarkers in a sample. More particularly, the disclosure relates to methods for treating the sample to liberate certain analytes prior to the assay. Composition for disrupting the HIV virus and antibody-antigen complex to release p24 antigen is also disclosed. The disclosed methods and compositions are compatible with existing HIV antigen/antibody combination assays and improve the sensitivity of such assays.
1 . A method for determining the level of one or more biomarkers in a sample, the method comprising:
a) contacting the sample with a composition to form a sample mixture, wherein the composition comprises an ionic detergent, a nonionic detergent, and a salt,
b) loading the sample mixture into a device comprising a waveguide, allowing the one or more biomarker to bind to one or more capture molecules immobilized on the waveguide,
c) adding one or more labeling molecules into the device, allowing the labeling molecules to bind to their respective biomarkers, and
d) measuring the signal intensity emitted from the labeling molecules that are bound to the immobilized biomarkers and capture molecules on the waveguide to determine the level of the one or more biomarkers in the sample.
2 . The method of claim 1 , wherein the sample is a member selected from the group consisting of whole blood sample, serum, plasma and saliva.
3 . The method of claim 1 , further comprising a step of raising temperature of said sample mixture to at least 70° C. after step (a) but before step (b).
4 . The method according to claim 1 , wherein the sample comprises a plurality of biomarkers comprising at least one antigen originated from a pathogen and at least one antibody against the pathogen, and wherein the device comprises a plurality of capture molecules, at least one group of capture molecules being capable of capturing said at least one antigen, and at least one other group of capture molecules being capable of capturing said at least one antibody.
5 . The method according to claim 1 , wherein the composition further comprises an anti-CD59 antibody.
6 . The method according to claim 1 , wherein the composition has a pH of lower than 3.5.
7 . The method of claim 6 , further comprising a neutralizing step after step (a) but before step (b).
8 . The method according to claim 1 , wherein the sample is a whole blood sample.
9 . The method according to claim 1 , wherein the composition comprises Triton® X-100 at a concentration of 2-3% (v/v), sodium deoxycholate at a concentration of 2-3% (w/v), sodium dodecyl sulfate (SDS) at a concentration of 0.3-0.8% (w/v), NaCl at a concentration of 0.5-1M, EDTA at a concentration of 10-25 mM, and Tris-CI, pH 7.4, at a concentration of 30-80 mM.
10 . The method according to claim 1 , wherein the sample is derived from a blood sample, wherein the one or more biomarkers comprise a protein originating from the human immunodeficiency virus (HIV), and said method being capable of producing a statistically significant positive signal from a sample having an HIV viral load of 300,000 copies/ml or lower.
11 . A composition for processing a sample to determine the level of a biomarker in the sample, said composition comprising
a) an ionic detergent, wherein the ionic detergent comprises deoxycholate;
b) a nonionic detergent, and
c) a salt.
12 . The composition of claim 11 , wherein the ionic detergent further comprises sodium dodecyl sulfate (SDS), wherein the SDS is present in the composition at a concentration of 0.1-1.5% (w/v).
13 . The composition of claim 11 , wherein the deoxycholate is sodium deoxycholate, and the sodium deoxycholate is present in the composition at a concentration of 1% to 5% (w/v)
14 . The composition of claim 11 , wherein the nonionic detergent comprises Triton® X-100, said Triton® X-100 being present in the composition at a concentration of 1-5% (v/v).
15 . The composition of claim 11 , wherein the composition is mixed with the sample at a certain ratio to form a sample mixture, wherein the concentration of the SDS in the sample mixture is in the range of 0.01-0.3% (w/v).
16 . The composition of claim 11 , wherein the deoxycholate is sodium deoxycholate, and wherein the composition is mixed with the sample at a certain ratio to form a sample mixture, the concentration of the sodium deoxycholate in the sample mixture being in the range of 0.1-1% (w/v).
17 . The composition of claim 11 , wherein the nonionic detergent comprises Triton® X-100, and wherein the composition is mixed with the sample at a certain ratio to form a sample mixture, the concentration of the Triton® X-100 in the sample mixture being in the range of 0.1-1% (v/v).
18 . The composition of claim 11 , further comprising an anti-CD59 antibody.
19 . The composition of claim 11 , wherein the composition comprises Triton® X-100 at a concentration of 2-3% (v/v), sodium deoxycholate at a concentration of 2-3% (w/v), sodium dodecyl sulfate (SDS) at a concentration of 0.3-0.8% (w/v), NaCl at a concentration of 0.5-1M, EDTA at a concentration of 10-25 mM, and Tris-CI, pH 7.4, at a concentration of 30-80 mM.
20 . The composition of claim 11 , wherein the composition comprises Triton® X-100 at a concentration of about 2.5% (v/v), sodium deoxycholate at a concentration of about 2.5% (w/v), sodium dodecyl sulfate (SDS) at a concentration of about 0.5% (w/v), NaCl at a concentration of about 0.75 M, EDTA at a concentration of about 17 mM, and Tris-CI, pH 7.4, at a concentration of about 50 mM.
21 . (canceled)
22 . A method for determining the level of one or more biomarkers in a sample, the method comprising:
a) contacting the sample with a composition to form a sample mixture, wherein the composition comprises an ionic detergent, a nonionic detergent, a salt, and one or more labeling molecules that bind to said one or more biomarkers,
b) loading the sample mixture into a device comprising a waveguide, allowing the one or more biomarkers to bind to one or more capture molecules immobilized on the waveguide, and
c) measuring the signal intensity emitted from the labeling molecules that are bound to the immobilized biomarkers and capture molecules on the waveguide to determine the level of the one or more biomarkers in the sample.